Qualigen Therapeutics, Inc., formerly Ritter Pharmaceuticals, Inc., is a biotechnology company. The Company is focused on the development and commercialization of therapeutic products for the treatment of cancer and infectious diseases, as well as development of its FastPack diagnostic platform. Its pipeline includes AS1411, Aptamer Linked Anti Nucleolin (ALAN), Aptamer Linked Anti Nucleolin - Contrast Enhancement (ALAN-CE), Aptamer Linked Anti Nucleolin - Radiation Enhancement (ALAN-RE), Selective Target Antigen Removal System (STARS) and RAS-F. The FastPack System is an immunoassay testing system, which consists of the FastPack Analyzer and the FastPack test pouch, a single-use, disposable, foil packet which includes the FastPack reagent chemistry. The Company’s subsidiary is Qualigen, Inc.